Estimating the economic costs of antimicrobial resistance: Model and Results

Jirka Taylor; Marco Hafner; Erez Yerushalmi; Richard Smith; Jacopo Bellasio; Raffaele Vardava; Teresa Bienkowska-Gibbs; Jennifer Rubin

Estimating the economic costs of antimicrobial resistance: Model and Results

Jirka Taylor, Marco Hafner, Erez Yerushalmi, Richard Smith, Jacopo Bellasio, Raffaele Vardava, Teresa Bienkowska-Gibbs, Jennifer Rubin

Research output: Book/Report › Commissioned report › peer-review

Abstract

The independent Review on AMR led by the economist Jim O'Neill commissioned RAND Europe to conduct a study estimating the global costs of antimicrobial resistance until 2050 in the absence of any progress in tackling the challenge. We developed a general equilibrium model, which calculated the extent of losses to the world economy caused by decreases in the supply of labour resulting from resistant hospital acquired infections and selected major infectious diseases (HIV, TB, malaria). Our approach incorporated a set of seven scenarios with varying rates of future resistance, time of onset of increases in resistance, and availability of effective second-line therapy.

Original language	English
Publisher	RAND Corporation
Volume	RAND_RR911
Publication status	Published (VoR) - 10 Dec 2014

Funding

The study has been commissioned by the Independent Review on Antimicrobial Resistance and supported by the Wellcome Trust.

Funders	Funder number
Wellcome Trust

Keywords

Antimicrobial Resistance
Computable General Equilibrium (CGE) model
Human capital

Access to Document

https://www.rand.org/pubs/research_reports/RR911.html

Cite this

@book{c5a271e1a24b4d6597c349a7cf83c2db,

title = "Estimating the economic costs of antimicrobial resistance: Model and Results",

abstract = "The independent Review on AMR led by the economist Jim O'Neill commissioned RAND Europe to conduct a study estimating the global costs of antimicrobial resistance until 2050 in the absence of any progress in tackling the challenge. We developed a general equilibrium model, which calculated the extent of losses to the world economy caused by decreases in the supply of labour resulting from resistant hospital acquired infections and selected major infectious diseases (HIV, TB, malaria). Our approach incorporated a set of seven scenarios with varying rates of future resistance, time of onset of increases in resistance, and availability of effective second-line therapy.",

keywords = "Antimicrobial Resistance, Computable General Equilibrium (CGE) model, Human capital",

author = "Jirka Taylor and Marco Hafner and Erez Yerushalmi and Richard Smith and Jacopo Bellasio and Raffaele Vardava and Teresa Bienkowska-Gibbs and Jennifer Rubin",

year = "2014",

month = dec,

day = "10",

language = "English",

volume = "RAND_RR911",

publisher = "RAND Corporation",

}

TY - BOOK

T1 - Estimating the economic costs of antimicrobial resistance: Model and Results

AU - Taylor, Jirka

AU - Hafner, Marco

AU - Yerushalmi, Erez

AU - Smith, Richard

AU - Bellasio, Jacopo

AU - Vardava, Raffaele

AU - Bienkowska-Gibbs, Teresa

AU - Rubin, Jennifer

PY - 2014/12/10

Y1 - 2014/12/10

N2 - The independent Review on AMR led by the economist Jim O'Neill commissioned RAND Europe to conduct a study estimating the global costs of antimicrobial resistance until 2050 in the absence of any progress in tackling the challenge. We developed a general equilibrium model, which calculated the extent of losses to the world economy caused by decreases in the supply of labour resulting from resistant hospital acquired infections and selected major infectious diseases (HIV, TB, malaria). Our approach incorporated a set of seven scenarios with varying rates of future resistance, time of onset of increases in resistance, and availability of effective second-line therapy.

AB - The independent Review on AMR led by the economist Jim O'Neill commissioned RAND Europe to conduct a study estimating the global costs of antimicrobial resistance until 2050 in the absence of any progress in tackling the challenge. We developed a general equilibrium model, which calculated the extent of losses to the world economy caused by decreases in the supply of labour resulting from resistant hospital acquired infections and selected major infectious diseases (HIV, TB, malaria). Our approach incorporated a set of seven scenarios with varying rates of future resistance, time of onset of increases in resistance, and availability of effective second-line therapy.

KW - Antimicrobial Resistance

KW - Computable General Equilibrium (CGE) model

KW - Human capital

M3 - Commissioned report

VL - RAND_RR911

BT - Estimating the economic costs of antimicrobial resistance: Model and Results

PB - RAND Corporation

ER -

Estimating the economic costs of antimicrobial resistance: Model and Results

Abstract

Funding

Keywords

Access to Document

Fingerprint

Cite this